Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news

First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen's quest to expand the use of Aduhelm and what it means for the treatment of Alzheimer's disease. Finally, Arrakis Therapeutics CEO Michael Gilman calls in to explain how targeting RNA can treat disease and why the characters in "Dune" don't just shoot each other with laser guns.

Episode metadata supplied by the publisher feed · Published Jan 13, 2022

Embed this episode

Attribution link and audio player

Ready to play

Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news

0:00 34:47

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 34 minutes long.

When was this The Readout Loud episode published?

This episode was published on January 13, 2022.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!